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There are various types of self-expandable metallic stent (SEMS) for biliary obstruction, but it is unknown which one is ideal. Ideal SEMS should prevent
recurrent biliary obstruction or other complications after SEMS placement until the patient’s death. In this review, risk factors for recurrent biliary
obstruction or complications are discussed. Based on the current literature, the combination of a high radial force and a low axial force is important. SEMS
should be fully covered with a smooth inner surface to prevent stent occlusion by tumor ingrowth, sludge, or food impaction. There are attempts to
further prolong time to recurrent biliary obstruction: a large bore SEMS to prevent stent occlusion by sludge or a SEMS with antimigration systems. Taking
these results of various SEMS into consideration, an ideal biliary SEMS should be further developed.
Copyright  2015, Society of Gastrointestinal Intervention. Published by Elsevier.
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What are the clinical features of optimal biliary self-expandable
metallic stents (SEMS)? Such stents are associated with longer
patency, lower incidences of stent occlusion, and fewer complica-
tions. However, the association between clinical events and stent
design remain poorly understood. We focus on this topic below.Tokyo criteria 2014
Stent occlusion may be caused by tumor ingrowth via the stent
mesh, tumor overgrowth, debris, food impaction, and other
events. Migration and bile duct kinking at the tips of the SEMS are
not viewed as occlusions, but nonetheless cause recurrent biliary
obstruction (RBO). Thus, we consider that stent patency alone
does not adequately reﬂect the quality of SEMS, and that RBO
should also be taken into consideration in its evaluation. Recently,
we proposed a new reporting system for the outcomes of trans-
papillary stenting termed “Tokyo criteria 2014”.1 We summarized
the items raised in Tokyo criteria 2014 for evaluating the function
of stents in Table 1.
In the present article, we consider the incidence of RBO, and the
time to RBO (TRBO), rather than stent occlusion and patency. RBO is
deﬁned as stent occlusion, stent migration, and kinking of the bile
duct. Employment of a uniform reporting system would facilitateDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Toky
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obtained by endoscopists worldwide.Mechanical properties of SEMS
The important mechanical properties of SEMS include the radial
force (RF) and the axial force (AF) exerted. RF is the well-known
expansion force that dilates the cavity and resists compression by
the tumor. AF is a new concept proposed by our group. This is the
recovery force that develops when the SEMS is bent, and we pre-
viously described the methods of measurements of AF.2 SEMS were
ﬁxed perpendicularly with a glass tube and it was bent with a force
gauge in the oven at a temperature of 37C. We measured AF in
three distances from bending point, 20 mm, 40 mm, and 60 mm.
We employed AF in a 60 angle and at 20 mm in distance from the
bending point for comparison of each SEMS. From our previous
article, SEMS with knitted structures tended to show a lower AF
than other types of SEMS (laser cut type and braided type e.g.,
Wallstent, Boston Scientiﬁc, Natick, MA). AF differs from ﬂexibility;
the latter is not a force but rather a property of the stent. A strong
AFmay be associated with poor conformability in the bile duct, and
may trigger stent migration. In the bile duct, SEMS are surrounded
by tumor tissue and the AF causes both sides of a SEMS to compress
the bile duct wall, the oriﬁce of the cystic duct, and the pancreatic
oriﬁce. Such phenomena may trigger certain complicationso, Japan
e, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
vier. Open access under CC BY-NC-ND license.
Table 2 Multivariate Analysis of Risk Factors for Early Migration (within 6
months) of Covered Self-expandable Metallic Stents (SEMS). Axial Force was not
Signiﬁcant
SHR (95% CI) P
Radial force < 4.00 N 2.23 (1.07–4.65) 0.03
Chemotherapy 4.46 (1.38–14.45) 0.01
Duodenal tumor invasion 2.25 (1.10–4.60) 0.02
CI, conﬁdence interval; N, Newton; SEMS, self-expandable metallic stent; SHR,
subdistribution hazard ratio.
Note. From “Risk factors for covered metallic stent migration in patients with distal
malignant biliary obstruction due to pancreatic cancer,” by Y. Nakai, H. Isayama, H.
Kogure, T. Hamada, O. Togawa, Y. Ito et al, 2014, J Gastroenterol Hepatol, 29, p. 1744–
9. Copyright 2014, Journal of Gastroenterology and Hepatology Foundation and Wiley
Publishing Asia Pty Ltd. Adapted with permission.
Table 1 Outcomes to be Described in Studies on Stents for Malignant Biliary
Obstruction
Technical and functional success rates
 Recurrent biliary obstruction (RBO)
‣ Incidence
‣ Median time to RBO (TRBO)
‣ Nonobstruction rates (3 mo, 6 mo, and 12 mo)
 Causes of RBO
‣ Occlusion: Tumor ingrowth/mucosal hyperplasia, tumor overgrowth,
sludge/stone, food impaction, hemobilia, kinking of bile duct, others
‣ Symptomatic migration (proximal or distal)
 Complications other than RBO
‣ Kinds: Pancreatitis, cholecystitis, nonocclusion cholangitis, and others
‣ Timing: Early (within 30 d) or late ( 31 d)
‣ Severity (See the original manuscript)
RBO, recurrent biliary obstruction; TRBO, time to recurrent biliary obstruction.
Note. From “TOKYO criteria 2014 for transpapillary biliary stenting,” by H. Isayama,
T. Hamada, I. Yasuda, T. Itoi, S. Ryozawa, Y. Nakai, et al, 2015, Dig Endosc, 27, p. 259–
64. Copyright 2014, Digestive Endoscopy  2014 Japan Gastroenterological Endoscopy
Society. Adapted with permission.
Table 4 Multivariate Analysis of Risk Factors for Pancreatitis after Self-
expandable Metallic Stent (SEMS) Placement. Radial Force was not Signiﬁcant
OR (95% CI) P
Axial force > 0.40 N 3.69 (1.19–16.2) 0.022
Etiology of malignant biliary
obstruction (nonpancreatic cancer)
5.52 (2.24–14.1) <0.001
Pancreatic duct injection 2.54 (0.99–6.35) 0.051
CI, conﬁdence interval; N, Newton; OR, odds ratio; SEMS, self-expandable metallic
stent.
Note. From “Risk factors for pancreatitis following transpapillary self-expandable
metal stent placement,” by Kawakubo K, Isayama H, Nakai Y, Togawa O, Sasahira N,
Kogure H, et al. Surg Endosc. 2012, 26:771–6. Copyright 2011, Springer
Science+Business Media. LLC 2011. Adapted with permission.
Table 3 Multivariate Analysis of Risk Factors for Cholecystitis after Self-
expandable Metallic Stent (SEMS) Placement. Radial Force was not Signiﬁcant
OR (95% CI) P
Axial force  0.40 N 5.33 (1.74–23.27) 0.002
Tumor involvement to OCD 5.40 (2.32–13.14) <0.001
Stent length  60 mm 3.19 (1.30–8.62) 0.010
CI, conﬁdence interval; N, Newton; OCD, oriﬁce of cystic duct; OR, odds ratio; SEMS,
self-expandable metallic stent.
Note. From “Metallic stent with high axial force as a risk factor for cholecystitis in
distal malignant biliary obstruction,” by Nakai Y, Isayama H, Kawakubo K, Kogure H,
Hamada T, Togawa O, et al. 2014, J Gastroenterol Hepatol. 2014;29(7):1557–62.
Copyright 2014  2014 Journal of Gastroenterology and Hepatology Foundation and
Wiley Publishing Asia Pty Ltd. Adapted with permission.
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We are of the view that SEMS must exert weak AFs.
Causes and prevention of RBO
RBO is caused by stent occlusion, stent migration, and kinking of
the bile duct at both ends of a stent. Stent occlusion results from
tumor ingrowth, tumor overgrowth, deposition of sludge and/or
stones, food impaction, and other events. Below, we consider ways
to prevent RBO.
Prevention of tumor ingrowth
Acoveringmembrane effectively prevents tumor ingrowth via the
SEMS mesh.3 However; poor membrane durability may be of
concern.4 Telford et al4 reportedhigh incidences of tumor ingrowth in
Wallstents with silicone membranes. However, SEMS with a poly-
tetraﬂuoroethylene (PTFE) cover showed very low incidences of
tumor ingrowth. Thus, the results of clinical studies using covered
SEMSmaydepend on the quality of both the cover and the stent body.
Prevention of tumor overgrowth and kinking of the bile duct
The most common cause of covered SEMS occlusion is tumor
overgrowth. We always make the covered SEMS as long as possible,
from the hilum to the duodenum. This prevents overgrowth and
kinking of thebile duct because longer SEMShave lowerAFs.2,5,6 Also,
in the management of hilar stricture with SEMS, high AF may cause
bile duct kinking because of acutely angled bile duct in a hilar lesion.7
Prevention of sludge formation
Occlusion caused by sludge is themost difﬁcult of all occlusions to
resolve. A SEMS is a foreign body, and a bacterial bioﬁlm may form
on the surface at any time. Our recent clinical study (WATCH-2)
evaluated fully covered Wallﬂex SEMS (Wallﬂex Biliary RX Stent,
Boston Scientiﬁc, Natick, MA) compared to partially coveredWallﬂex
SEMS (a historical control).8 The extents of TRBO were similar. The
incidence of stent occlusion caused by sludge formation was very
low. Other clinical trials using large-diameter fully covered SEMSfound no occlusion caused by sludge. In another study, we evaluated
Niti-S SUPREMO 12 SEMS (diameter 12 mm, fully silicone-covered,
made with nitinol; Taewoong Medical Devices, Seoul, Korea).9
Thus, recent studies show that fully covered SEMS of larger di-
ameters are associated with low incidences of sludge formation.
Prevention of food impaction
Previously, we evaluated Niti-S (Niti-S stent, D-type; Taewoong
Medical Devices, Seoul) and ComVi (Niti-S stent, ComVi type; Tae-
woong Medical Devices, Seoul) stents (which have almost no AF) in
this context. In a clinical study, the incidences of food impaction
using these SEMS were signiﬁcantly higher than when partially
covered Wallstents were employed. The ComVi stent is triple-
layered, and sandwiching of the e-PTFE membrane between two
uncovered SEMS affords a very low AF.10 The AF of the ComVi stent is
very low but naked wires are exposed on both the outer and inner
surfaces. The outer uncovered portion may serve as an anchor to
prevent migration, but the fact that the inner portion is uncovered
increases the incidence of food impaction. However, in theWATCH-2
study, the incidence of food impaction was low.8 The work shows
that fully covered SEMS with smooth inner surfaces should be used
to prevent food impaction. Another candidate for the prevention of
food impaction is SEMS with an antireﬂux system. There was no
Table 5 Risk Factors for Self-expandable Metallic Stent (SEMS) Dysfunction (Recurrent Biliary Obstruction) and SEMS-related Complications




Tumor overgrowth Short length Cholangiocarcinoma
Bile duct kinking High axial force
Short length (leading to high axial force)
Food impaction/sludge Irregular inner surface Duodenal tumor invasion
Placement across the papilla Duodenal metal stent
Small diameter
Uncovered and partially-covered type
Migration Covered type Chemotherapy
Low radial force Duodenal tumor invasion
Without anti-migration system
Complications
Cholecystitis High axial force Tumor involvement to OCD
Short type
(leading to high axial force)
Pancreatitis High axial force Nonpancreatic cancer
Pancreatic duct injection




OCD, oriﬁce of cystic duct; SEMS, self-expandable metallic stent.
Gastrointestinal Intervention 2015 4(1), 46–4948evidence of the beneﬁts of an antireﬂux SEMS previously, however,
an article revealed its efﬁcacy. Hu et al11 published about superiority
of covered SEMS with antireﬂux to uncovered SEMS by randomized
controlled trial. This trial is difﬁcult to understand because we could
not determine which is more useful, covering or an antireﬂux sys-
tem. Hamada et al12 studied the usefulness of antireﬂux covered
SEMS in revision cases with occluded stent due to food impaction.
This situation was considered as high-risk for food impaction again.
We thought that antireﬂux covered SEMS may be effective in high
risk cases of food impaction; occluded due to food impaction,
duodenal tumor invasion, and cases with duodenal SEMS.13,14Prevention of migration
The Achilles’ heel of covered SEMS is migration. An advantage is
that the SEMS are removable, but a trade-off relationship is in play.
In the WATCH study, we compared partially coveredWallﬂex SEMS
with partially covered Wallstents, and found that the former stents
had a lower incidence of migration.15 Compared to the Wallstent,
the Wallﬂex exhibited 40% more RF and 30% less AF and provided
ﬂare at both ends, explaining the favorable results. We found that
risk factors for migration of covered SEMS (n ¼ 314 cases) included
RF and chemotherapy (Table 2).16 Recently, antimigration systems
have been developed. Park et al17 reported that ﬂaps effectively
prevented migration. Other antimigration systems include both
ﬂares and banks,18 outer uncovered regions,10 and variation in RF.19
Use of the latter approach affords SEMS a unique structure,
featuring both strong and weak RF regions over the body of the
stent. Such strength heterogeneity may allow SEMS to become
anchored in the bile duct.20 Antimigration is very important for the
improvement in results of the covered SEMS, but the ideal anti-
migration system is unknown. The authors personally thought that
a combination of a good balance of mechanical properties and other
mechanical antimigration systems was promising.
Prevention of cholecystitis and pancreatitis
Cholecystitis
We employed both uni- and multivariate analyses to explore
risk factors for cholecystitis; tumors involving the oriﬁce of thecystic duct and a strong stent AF were signiﬁcantly predictive of
post-SEMS placement cholecystitis (Table 3).21–23
Pancreatitis
Many endoscopists believe that a sphincterectomy effectively
prevents pancreatitis. However, some articles have reported
disappointing results. We earlier found that a strong stent AF and
the presence of nonpancreatic cancer were signiﬁcantly predictive
of pancreatitis (Table 4).24 A strong AF may cause SEMS to block the
oriﬁce of the pancreatic duct, causing pancreatitis to develop
because the ﬂow of pancreatic juice is obstructed. Complete
sphincterectomy may also cause pancreatitis.
The ideal structure of SEMS
An ideal SEMS would not cause any complications over a pa-
tient’s lifetime. Such a SEMS must have a high RF and (especially) a
low AF, be fully covered, and have a smooth inner surface (to pre-
vent food impaction). To reduce sludge formation, full coverage and
a large stent diameter are important. In addition, incidence of
migration may be reduced using antimigration systems, thereby
increasing the TRBO.We summarize the risk factors of RBO in SEMS
placement in Table 5.
It is very difﬁcult to describe an ideal pattern of braiding or
weaving. However, the ideal stent should have a low AF, a high RF,
be fully covered, be of maximal possible diameter, and feature an
antimigration system. Such SEMS would optimize a patient’s
quality-of-life.
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